Treatment Sequences After Discontinuing a Tumor Necrosis Factor Inhibitor in Patients With Rheumatoid Arthritis: A Comparison of Cycling Versus Swapping Strategies-Reference-Cited by-同舟云学术

Treatment Sequences After Discontinuing a Tumor Necrosis Factor Inhibitor in Patients With Rheumatoid Arthritis: A Comparison of Cycling Versus Swapping Strategies

Published:2021-08-26 Issue:10 Volume:73 Page:1461-1469
ISSN:2151-464X
Container-title:Arthritis Care & Research
language:en
Short-container-title:Arthritis Care Res

Author:

Karpes Matusevich Aliza R.¹^ORCID,Duan Zhigang²,Zhao Hui²^ORCID,Lal Lincy S.¹,Chan Wenyaw¹,Suarez‐Almazor María E.²^ORCID,Giordano Sharon H.²^ORCID,Swint J. Michael³,Lopez‐Olivo Maria A.²^ORCID

Affiliation:

1. School of Public Health The University of Texas Health Science Center at Houston

2. The University of Texas MD Anderson Cancer Center Houston

3. School of Public Health and McGovern School of Medicine The University of Texas Health Science Center at Houston

Funder

Rheumatology Research Foundation

Publisher

Wiley

Subject

Rheumatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr.24358

Reference47 articles.

1. Coverage for High-Cost Specialty Drugs for Rheumatoid Arthritis in Medicare Part D

2. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta‐analysis of drug registries and health care databases;Souto A;Rheumatology (Oxford),2016

3. A review of uses of health care utilization databases for epidemiologic research on therapeutics

4. Comparative effectiveness research with administrative health data in rheumatoid arthritis

5. Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics of clinical manifestations and pharmacotherapy in patients with rheumatoid arthritis requiring switching between biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors;Modern Rheumatology Journal;2024-08-20

2. Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas y sintéticas dirigidas en la artritis reumatoide;Reumatología Clínica;2024-07

3. Which advanced treatment should be used following the failure of a first-line anti-TNF in patients with rheumatoid arthritis? 15 years of evidence from the Quebec registry RHUMADATA;Rheumatology;2024-06-03

4. Real‐World Treatment and Care Patterns in Patients With Rheumatoid Arthritis Initiating First‐Line Tumor Necrosis Factor Inhibitor Therapy in the United States;ACR Open Rheumatology;2024-01-14

5. One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib;Advances in Therapy;2023-08-05